Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Andra AP fonden Boosts Stake in Incyte Corporation $INCY
03:15am, Friday, 27'th Feb 2026
Andra AP fonden lifted its holdings in shares of Incyte Corporation (NASDAQ: INCY) by 24.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange
Incyte Corporation $INCY Shares Bought by Citigroup Inc.
04:44am, Wednesday, 25'th Feb 2026
Citigroup Inc. grew its position in Incyte Corporation (NASDAQ: INCY) by 187.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commi
Aberdeen Group plc Grows Stock Position in Incyte Corporation $INCY
04:42am, Friday, 20'th Feb 2026
Aberdeen Group plc lifted its position in Incyte Corporation (NASDAQ: INCY) by 24.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission
Incyte Remains Undervalued As Opzelura And Niktimvo Scale
10:38pm, Wednesday, 18'th Feb 2026
Incyte started 2026 on a high note. On January 7, its stock hit an all-time high of $112.29. In my view, the key drivers of raised investor interest in Incyte are the strong performance of its ruxolit
Incyte to Present at Upcoming Investor Conferences
08:00am, Tuesday, 17'th Feb 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conferenc
Cookson Peirce & Co. Inc. Acquires Shares of 11,331 Incyte Corporation $INCY
03:54am, Saturday, 14'th Feb 2026
Cookson Peirce and Co. Inc. bought a new stake in Incyte Corporation (NASDAQ: INCY) during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 1
Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells
05:45am, Friday, 13'th Feb 2026
Baird Chautauqua International Growth Fund underperformed its benchmark as stock selection in health care and consumer discretionary detracted most from relative returns. Fanuc reported September quar
Incyte Q4 Earnings Call Highlights
05:34am, Thursday, 12'th Feb 2026
Incyte (NASDAQ: INCY) executives highlighted stronger-than-expected 2025 commercial performance, an increasingly late-stage pipeline, and multiple regulatory milestones during the company's fourth qua
Incyte: Why The Market Is Overreacting To A Guidance 'Miss'
11:03am, Wednesday, 11'th Feb 2026
Incyte experienced an 8.2% sell-off after 2026 guidance appeared to miss consensus by $680M, but this was due to a royalties accounting nuance. Adjusted for royalties, INCY's 2026 sales guidance is ne
Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
03:44pm, Tuesday, 10'th Feb 2026
Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
Incyte Corp (INCY) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Pipeline Advancements Amid Market Challenges
02:03pm, Tuesday, 10'th Feb 2026
Release Date: February 10, 2026For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Incyte Corp
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
11:40am, Tuesday, 10'th Feb 2026
Incyte posts a Q4 EPS miss but a 28% revenue jump, fueled by Jakafi and Opzelura strength, as product sales top estimates.
Incyte (INCY) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
10:30am, Tuesday, 10'th Feb 2026
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare
Incyte (INCY) Q4 Earnings Lag Estimates
09:15am, Tuesday, 10'th Feb 2026
Incyte (INCY) came out with quarterly earnings of $1.8 per share, missing the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $1.43 per share a year ago.
Incyte weak 2026 revenue forecast heightens Jakafi patent concerns
08:13am, Tuesday, 10'th Feb 2026
Incyte forecast annual sales below Wall Street estimates on Tuesday with its key growth driver Opzelura expected to underperform, raising concerns about the drugmaker's ability to offset looming paten
